{"abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","action":"Notice; establishment of a public docket; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/07/08/2026-13810.html","cfr_references":[],"citation":"91 FR 42203","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The meeting will be held on July 30, 2026, from 10:00 a.m. to 4:30 p.m. Eastern Time.","disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-7231"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":141,"comment_start_date":"2026-07-08","updated_at":"2026-07-30T01:56:24.602-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-7231-0001","allow_late_comments":false,"id":"FDA-2026-N-7231-0001","comment_end_date":"2026-07-30","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2026-N-7231","title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec."}],"document_number":"2026-13810","effective_on":null,"end_page":42204,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/07/08/2026-13810.xml","html_url":"https://www.federalregister.gov/documents/2026/07/08/2026-13810/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-13810?publication_date=2026-07-08","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-07-08/2026-13810/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":624,"last_updated":"2026-08-24 20:15:14 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-08/pdf/2026-13810.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13810.pdf?1783428319","publication_date":"2026-07-08","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/07/08/2026-13810.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":141,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-7231","supporting_documents_count":0,"docket_id":"FDA-2026-N-7231","document_id":"FDA-2026-N-7231-0001","regulation_id_number":null,"title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec.","checked_regulationsdotgov_at":"2026-07-31T08:55:03Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":42203,"subtype":null,"title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec","toc_doc":"Cellular, Tissue, and Gene Therapies Advisory Committee; Biologics License Application 125827, from Replimune, Inc. for vusolimogene oderparepvec","toc_subject":"Hearings, Meetings, Proceedings, etc.","topics":[],"type":"Notice","volume":91}